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iii Researchers have discovered that information about hearing sensitivity at frequencies beyond this standard range may provide valuable information for clinical and research applications (Fausti, Frey, Erickson, Rappaport, & Cleary, 1979) . One application of high frequency audiometry is for early detection of ototoxic damage (Dreschler, Hulst, Tange, & Urbanus, 1989) .
A standard physiological method of obtaining audiometric information is through the use of otoacoustic emissions. Otoacoustic emissions are an indirect physical measurement of the outer hair cell function ofthe cochlea, and are not dependent on a behavioral response (Hall, 2000) . There are four types of otoacoustic emissions: Spontaneous (SOAE), Stimulus Frequency (SFOAE), Transient (TEOAE), and Distortion Product otoacoustic emissions (DPOAE). Two types, transient, and distortion product otoacoustic emissions, are applied clinically (Hall, 2000) . An example of the application of otoacoustic emissions is monitoring for the ototoxic effects of medications (Stavroulaki, Apostopoulos, Segas, Tsakanikos, & Adamopoulos, 2001 (Jordan & Roland, 2000) .
The effects of medications are thought to be expressed throughout many areas of the auditory system. Areas affected may include the outer hair cells in the mid turn and basal turn organ of Corti, and neurons in the spiral ganglion (Gabaizadeh et aI., 1997) . The stria vascularis may also demonstrate severe degenerative changes (Hulst, Dreschler, and Urbanus, 1988) . At the cellular level, it is theorized that medications can result in an increase of intracellular calcium, thereby adversely affecting cell membranes, and ultimately resulting in magnesium deficiency (Cevette, Drew, Webb and Marion, 2000) .
Ototoxic damage to the auditory system may manifest itself clinically as an initial bilateral high frequency sensorineural hearing loss, which may progress to a loss in sensitivity at all frequencies (Jerger & Jerger, 1981) . This dysfunction is most often identified through the application of pure tone audiometry.
Many studies have evaluated changes in the auditory system with pure tone audiometry in patients using ototoxic medications. In one such study measuring from 250-8000 Hz for patients undergoing carboplatin chemotherapy administered in conjunction with osmotic opening of the blood-brain barrier, post treatment auditory threshold shifts were identified at 4000 and 8000 Hz (Doolittle et aI., 2001 ). This identification of changes in auditory thresholds supported the need for prospective High Frequency Correlations 3 monitoring of frequencies higher than 8000 Hz for patients enrolled in platinum based chemotherapy clinical trials.
When comparing the detectability for ototoxic damage between low frequency and high frequency pure tone audiometry, a 1989 study by Dreschler et aI. (1989) found that 34-77% of ears with ototoxic damage were discovered in an earlier stage when using high frequency audiometry. This study also concluded high frequency damage is present earlier than low frequency damage, with 12000 and 14000 Hz being the best test frequencies for the detection of ototoxicity (Dreschler et aI., 1989) .
Conventional and high frequency pure tone audiometry have been applied in case studies of patients receiving cisplatin chemotherapy (Fausti, Schechter, Rappaport, Frey & Mass, 1984) . Significant changes in consecutive high frequency thresholds were revealed in eight of thirteen patients. When comparing low and high frequency audiometric configurations, it was found that the magnitude of change was greater in the high frequency range of 8000 Hz-20000 Hz (Fausti et aI., 1984) Many studies have not only applied conventional audiometry to the evaluation of patients using ototoxic medications, but have added otoacoustic emissions to their regimen as well. Because the presence of an evoked otoacoustic emission is correlated with normal to near normal hearing thresholds, emissions can reflect the state of the cochlea (Avan & Bonfils, 1993 In a 1998 study of 12 children with a mean age of7.8 years, transient evoked otoacoustic emissions (TEOAE's) from 1000-5000 Hz were measured and compared to behavioral thresholds before and after a cisplatin chemotherapy regimen (Allen et aI., 1998) . Consistent with the literature (Doolittle et aI., 2001) , hearing loss of greater than 25 dB HL occurred in 81% of participants in this study at levels higher than 4000
Hz. When TEOAE reproducibility was compared with pure tone thresholds, it was found that the emission amplitudes correlated highly with pure tone audiometry findings.
When comparing TEOAE's, DPOAE's and pure tone audiometry in a pediatric oncology population undergoing cisplatin chemotherapy (Stavroulaki et aI., 2001) (Fausti et aI., 1979) . This system employs the use of a high output, low noise amplifier/filter for high fidelity, and an earphone that includes a ceramic diaphragm to provide a relatively flat response from 8000-20000 Hz (Fausti, Rappaport, Schechter, & Frey, 1982) .
This system for evaluating hearing sensitivity includes obtaining threshold information in the conventional frequencies from 250-8000 Hz by applying the standard audiometric procedure of Hughson-Westlake technique in 5 dB increments.
Second, high frequency thresholds are then obtained from 8000-20000 Hz, using a 2 dB bracketing tectmique (Fausti et aI., 1984) .
When recruiting participants to assess this high frequency measurement system, a survey evaluating frequencies above 12000 Hz found applicants to have highly variable hearing sensitivity on average, with medical history not accounting for the differences in hearing thresholds. The 21 participants from this survey demonstrated mean thresholds from 500-12000 Hz to be less than or equal to 20 dB SPL, rising slightly to 35 dB SPL at 17000 Hz, then increasing to 82 dB SPL at 20000
Hz (Fausti et aI., 1979) .
Application of this high frequency system discovered participants to have a progressive sloping response from 8000-20000 Hz. Mean between test differences for High Frequency Correlations 7 high frequency thresholds revealed no variations in thresholds greater than 4 dB (Fausti et aI., 1979 
Sites of ototoxic damage
The exact mechanisms affected by cisplatin are not known (Allen et aI., 1998) however; outer hair cell degeneration is a consistently reported side effect of patients In comparing which frequencies are damaged by cisplatin ototoxicity, Mc
Alpine et aI. (1990) discovered that "there are no differences in the susceptibility of high and low frequency regions of the cochlea, but that the higher frequency regions are more permeable to cisplatin." Studies evaluating the audiometric configuration of cisplatin ototoxicity demonstrate these effects in that the first area of the cochlea to suffer hearing loss is the high frequency region (Fausti et aI., 1984; Dreschler, Hulst, Tange & Urbanus, 1985) .
Other areas reportedly affected by ototoxic agents are the mid turn, and basal turn organ of Corti and the spiral ganglion. In animal studies analyzing the otoprotective effects ofD-methionine, (Gabaizadeh et al., 1997) 
Cisplatin and carboplatin chemotherapy agents
Cisplatin is a potent antineoplastic agent effective against a variety of tumors (McAlpine et aI., 1990) . Cisplatin has exhibited a broad spectrum of activity against epithelial cancers and has become the "foundation of curative regimens for testicular and ovarian cancers". It has also demonstrated significant activity against cancers of the head and neck, esophagus, lung, bladder, cervix, and endometrium (Go et aI., 1999) .
Various toxic side effects have been observed after cisplatin treatment, including severe renal, neurologic, cytotoxic and emetogenic effects (Go et al. 1999) .
Other associated side effects may also include myelosuppression, gastrointestinal dysfunction, ototoxicity, and vestibulotoxicity (Hulst et aI., 1988).
In 1981 carboplatin, an analog of cisplatin was introduced to circumvent some of the toxicities of cisplatin. Both are platinum complexes, but their compounds differ in that cisplatin contains two chloride "leaving" groups and carboplatin has a cyclobutane group (Go et aI., 1999) . Because carboplatin and cisplatin share a similar High Frequency Correlations 9 structure, they undergo the same chemical reactions and both target DNA as their major cytotoxic target. Concentration of the two drugs vary however, in that carboplatin requires 10 times higher drug concentration and longer incubation time to induce the same degree of change on DNA (Go et aI., 1999) .
It has been revealed that carboplatin displays less nephrotoxicity, ototoxicity, and neurotoxicity than cisplatin (as cited in Neuwelt et al., 1998; Go et aI., 1999) Renal impainnent is rare under carboplatin chemotherapy, except at extremely high doses (Hulst et aI., 1988) and carboplatin nausea and vomiting are less severe and frequent as compared to cisplatin (Go et al., 1999) .
It is believed that carboplatin and cisplatin may have different sites of damage to the auditory system. It has been established that carboplatin exerts toxic effects on inner hair cell function, whereas cisplatin's effects are exhibited on outer hair cell function (Hoffstetter, Ding, Powers, & Salvi, 1997) . These findings may have a significant impact on threshold monitoring, in that DPOAE's are independent of inner hair cell function (Hall, 2000) . DPOAE's rely on functional outer hair cells for auditory threshold monitoring. According to Hall (2000) , clinical protocols in monitoring for carboplatin ototoxicity should include measures of inner hair cell function such as pure tone audiometry or auditory brain stem response.
Use of otoprotectants
Due to the nephrotoxic, neurotoxic, myelosuppressive, and ototoxic mechanisms of cisplatin chemotherapy (Go et aI., 1999) researchers have evaluated the effects of using chemoprotectants in combination with platinum chemotherapy agents High Frequency Correlations 10 in clinical and pre-clinical settings (Neuwelt et aI., 1996; Gabaizadeh et aI., 1997; Neuwelt et al., 1998; Campbell et ai. 1998; Doolittle et aI, 2001) . A potential chemoprotectant against carboplatin-induced ototoxicity is delayed high dose sodium thiosulfate (STS). STS is effective as an otoprotectant when carboplatin is administered in conjunction with osmotic opening of the blood-brain barrier (Doolittle et aI., 2001) . Agents that may provide protection against cisplatin-induced ototoxicity may include D-:-methionine (Campbell et. al, 1997) . The mechanism ofSTS protection against carboplatin ototoxicity is unclear. It is currently theorized that the cochlea may act similar to the kidney to concentrate STS in the perilymph or endolymph. High concentrations of STS may act to inactivate carboplatin at the site of cochlear damage (Neuwelt et al. 1996) . This inactivation is thought to occur through the chemical reaction of the thiol binding to the electrophile platinum, thus rendering the platinum inactive (Neuwelt et aI., 1998 , Doolittle et al, 2001 ).
Animal studies evaluating carboplatin ototoxicity in a guinea pig model demonstrated protection when STS was given up to eight hours subsequent to carboplatin (Neuwelt et al., 1996) . Determination of the effect of STS on carboplatin induced ototoxicity was by electrophysiological measurements and cochlear hair cell count (Neuwelt et al., 1996) .
Studies evaluating the efficacy of high dose STS in patients with malignant brain tumors, noted what appeared to be a preservation of hearing (Neuwelt et aI., 1998 Patients with excellent baseline hearing (thresholds < 20 dB HL in the frequency range of 250-8000 Hz) showed little change in high frequency thresholds with a mean loss of 8 ± 5.6 dB after the first carboplatin followed by STS treatment. In comparison, patients in the (no STS) historical group with excellent baseline hearing thresholds, demonstrated a mean hearing loss of30.0 ± 8.4 dB after the first carboplatin treatment (Neuwelt et aI., 1998) .
This 1998 study further demonstrated that 50% of patients with impaired baseline hearing (thresholds> 20 dB HL in the frequency range of250-8000 Hz)
developed an additional 20 dB threshold shift, despite treatment with one dose of STS (Neuwelt et al. 1998 ). Because of this finding, the treatment regimen was altered.
Patients with impaired baseline hearing thereafter received a second dose of STS, 6
hours following carboplatin treatment (Doolittle et aI., 2001) .
In a more recent study, audiologic data from patients who received STS two (or two and six) hours after carboplatin, and patients who received STS four (or four and eight) hours after carboplatin, were compared with the historical (no STS) group.
Spearman rank correlation coefficients showed decreased rates of ototoxicity, with greater decay in STS (Doolittle et aI., 2001 ).
Otoacoustic Emissions
Otoacoustic emissions (OAE's) are the result ofbiomechanical activity associated with normally functioning outer hair cells. This motility produces a signal within the cochlea that is transmitted through the middle ear and ossicles. The signal is High Frequency Correlations 12
then measured with a microphone inserted into the ear canal (Gelfand, 1997). Because
OAEs can reflect the state of the cochlea, they are applied clinically to provide an objective measure of auditory sensitivity (Hall, 2000) . There are two general categories of otoacoustic emissions, spontaneous and evoked.
Spontaneous otoacoustic emissions (SOAEs) are emissions that occur in the absence of external stimuli. They consist of energies at one or more frequencies emitted by the normal ear (Hall, 2000) . SOAEs are most commonly detected in the 1000-2000 Hz region where reverse transmission through the middle ear is most efficient (Kemp, 1986) . Clinical application of SOAEs are limited, as they can be detected in only 50% of ears with normal hearing, with a genetic preference for females, they have variable amplitudes over time, and frequencies at which they occur are limited (Lonsbury-Martin et aI., 1991).
Evoked otoacoustic emissions are emissions that occur in response to presentation of an acoustic stimulus. These emissions can be further categorized into three subtypes according to the stimuli used to elicit them. Transient evoked emissions (TEOAEs) are elicited by a click, or toneburst; stimulus frequency (SFOAEs) are evoked by a single continuous pure tone; and acoustic distortion products (DPOAEs) are generated in response to two continuous pure tones separated using a prescribed frequency difference (Lonsbury-Martin et aI., 1991).
SFOAEs are emissions that are evoked using a constant pure tone stimulus presented at a low intensity level swept or changed slowly across a region of frequencies (Hall, 2000) . SFOAEs are more difficult to analyze than other types of High Frequency Correlations 13 emissions, because it is necessary to separate the SFOAE from the stimulus tone that is simultaneously present in the ear canal, and is larger than the emission (Lonsbury Martin et.al. 1991 ). There are currently no available devices for recording SFOAEs; therefore they are the least studied experimentally, and clinically (Hall, 2000) .
TEOAEs are acoustical signals emitted by outer hair cells of the cochlea on presentation of transient stimuli, such as clicks, or tone bursts (Ferguson, Smith, Davis, & Lutman, 2000) . TEOAE's are a waveform that is generated in the cochlea, and detected in the ear canal several milliseconds following presentation of a stimulus (Gelfand, 1997). The average latency, or time between waveforms is typically 5-20 milliseconds; time averages tend to decrease with increase in OAE frequency. Spectral analysis of these waveforms can provide frequency specific information across the frequency region from 0-5000 Hz (Gelfand, 1997).
Click evoked emissions, such as TEOAE's are thought to reflect the presence of outer hair cell function of the cochlea. When sensitivity tuning of the inner ear is impaired within a certain frequency range, spectral components of the TEOAE within that same frequency range are expected to be altered (Avan, Elbez, & Bonfils, 1997) .
This phenomenon supports the clinical utility of TEOAEs in monitoring the state of the cochlea in areas such as newborn infant hearing screening and ototoxicity monitoring (Allen et al, 1998) .
DPOAEs are emissions that are elicited by the simultaneous presentation of two pure tones, called primaries, closely spaced in frequency. The two primaries activate the cochlea in the same region of the basilar membrane, but due to nonlinear High Frequency Correlations 14
properties of a healthy cochlea, a third combination tone is generated in the frequency region where the two primary frequencies overlap. This is combination tone called an acoustic distortion product (Hall, 2000) .
The strongest DPOAE in human ears occurs at the cubic difference frequency, 2f1-f2, in which f1 represents the lower frequency stimulus, and f2 represents the higher frequency primary (Lonsbury-Martin et aI., 1991). DPOAE amplitudes may vary with the level of the primary tones, as an increase in level of the primaries results in an increase emission size (Gelfand, 1997).
Research supports that DPOAE amplitudes provide information as to the frequency specificity of the cochlea (Avan et aI, 1993; Moulin, Bera & Collet, 1994) .
When analyzing DPOAE amplitudes elicited by low frequency primaries, researchers have found significant correlations with auditory thresholds at the mean frequencies of the primary tones.
DPOAEs can be measured using two methods; a DPOAE audiogram, which
shows DPOAE amplitude as a function of the geometric mean (generation site) of the two frequencies, or an input/output function, which measures DPOAE amplitude as a function of stimulus level at a given frequency (Lonsbury-Martin, et aI, 1991).
Because of their high sensitivity, reliability, an~ objectivity, DPOAEs are used routinely as a measure of hearing sensitivity not only for patients using ototoxic medications, but for patients unable to perform behavioral testing, newborn and infant testing, testing persons with multiple disabilities, and malingerers (Stavroulaki et aI, 2001 L2 and L1levels were set to 65 dB and 55 dB SPL. The F11F2 ratio was set at the default setting of 1.2 (Hall, 2001 ). Fausti et al. (1984) , standard audiologic techniques were employed to obtain thresholds from 250-8000 Hz, and a modified Hughson-Westlake technique in 2 dB increments were used to obtain pure tone thresholds from 8000-20000 Hz.
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RESULTS
High frequency DPOAEs and pure tone thresholds were collected from 29
participants. This yielded information on these two types of measurements from a total of 50 ears.
Examples ofDPOAE amplitudes recorded from one subject are given in figure   1A . Each plot shows amplitude of sound recorded in the ear canal as a function of frequency. Two tones were presented to this subject's ears. The Fl primary was presented at 1810Hz, stimulating at a level of 65 dB SPL. The F2 primary was presented at 2211 Hz. The amplitude of the F2 stimulus was 55 dB SPL. These two tones resulted in a distortion product at a frequency of2F1-F2, which in this case was 1409 Hz. The measured amplitude was 16 dB SPL Figure 1 B is a graph of an acoustic distortion product generated with higher frequency primaries on the same subject. The Fl primary was presented at 5125 Hz at a level of 65 dB SPL. The F2 stimulus was presented at 6250 Hz. The F2 intensity was 55 dB SPL. When using 5125 and 6250 as the two primaries, this resulted in a 2FI-F2 frequency of 4001 Hz. The amplitude of the DPOAE was 8 dB SPL. As the stimulus frequency increases above 2000 Hz, the distortion product amplitudes are expected to reduce (Hall, 2000) . The difference between the amplitude of the DPOAE between figures 1 and 2 was 8 dB. primaries and the resulting 2Fl-F2 DPOAE in a mid frequency region for one subject. testing. This measure varied with each subject, but in this case was below -10 dB SPL. As demonstrated in figure 2, distortion product amplitude tend to decrease with increasing frequency.
In Figure 3 distortion product amplitude is plotted as a function of F2 Frequency for all subjects. As with the individual data in Fig. 2 , the group data in Fig.   3 tend to show a decline in DP level with increasing frequency. The mean amplitude from 2211-3717 Hz was 5.7 dB SPL, the mean amplitude from 4421-8832 Hz was 1.4 dB SPL, and the mean amplitude from 10505-17675 Hz was -1 dB SPL. The amplitude range throughout the frequency spectrum from 2211 to 17675 Hz was an average of27 dB SPL from 2211-3717 Hz, an average range of27 dB SPL from 4421 8832 Hz, and an average range of32 dB SPL from 10505-17675 Hz. Thus amplitude variability appears to be similar across frequencies. ~ primaries and the resulting 2FI-F2 DPOAE in a high frequency region for one subject.
-a. Two of the bivariate correlations, 12000 and 14000 Hz were found to be significant at the .05 level. One frequency, 4000 Hz, was found to be significant at the .01 level, with an r-value = -.461, indicating a moderate negative correlation. Significance (2-tailed)
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The scatter plots in figure 5A , 5B, and 5C illustrate the relationship between the objective and sUbjective measurements of hearing sensitivity for all subjects at the three frequencies with high correlation. If the variables are correlated as suspected, a diffuse clustering of data points spread around a downward sloping pattern is expected. Figure 5A is a scatter plot that displays 4000 Hz pure tone thresholds as a function of 4421 Hz DPOAE amplitudes. Each data point on the graph represents a subject response. Figure 5B is a scatter plot that displays the relationships of the 12500 Hz pure tone thresholds and 12500 Hz DPOAE amplitudes in all SUbjects. Figure 5C is a scatter plot that displays 14858 DPOAE amplitudes and 14000 Hz pure tone thresholds in all subjects. The correlations between the two measures therefore appear to be weak.
High Frequency Correlations 29 This trend is consistent with the findings, as stimulus frequency increases above 2000
Hz, a progressive reduction of DP amplitude for higher frequency stimuli were recorded when the fl/f2 ratio is kept at 1.22 (Hall, 2000) . The present study indicates that the decline continues to F2 values as high as 17,675 Hz. Our data also demonstrated an increase in behavioral thresholds with increasing frequency. This is consistent with the findings of Fausti et aI., 1979 , who showed that thresholds for normal hearing individuals increase with test tone frequencies from 8000-20000 Hz.
The literature has established significant correlations between DPOAEs and pure tone audiometry when evaluating the frequency range from 250-8000 Hz (A van et.al, 1993; Moulin, Bera & Collet, 1994) . Our data show a relatively poor correlation between the two types of measures within this range of frequencies and for frequencies above 8000 Hz. Possible reasons for the discrepancy in our findings are discussed
below.
An inherent problem with behavioral pure tone thresholds, is the fact that they are a subjective measurement at risk to variability. When performing a Pearson r correlation analysis between repeated measures, all thresholds were found to have a high statistical significance, with an r-value of at least .905 for all frequencies tested from 9000 through 16000 Hz. This indicates a high level of reproducibility between High Frequency Correlations 33 repeated measures. The range of high frequency thresholds was found to be within the clinically acceptable range of ± 10 dB SPL for repeated thresholds (Frank et.al., 1991) .
It is therefore unlikely that the low correlation was due to poor reliability of our behavioral thresholds.
Repeated measures were not performed on OAEs because they are generally not subject to patient variability, so an evaluation of equipment was performed. The
Intelligent Hearing Systems (IHS) is the only commercially available device capable of measuring high frequency DPOAEs for a clinical setting. There are currently no ANSI standards for high frequency measurements, so protocols and calibrations were performed using the manufacturer's recommendations with the software and probe tips recommended by IHS.
As outlined in the methods section, measurement of the transducer output using a 1 cc coupler was performed prior to data collection to evaluate sthnulus purity.
Emissions should not exist in a hard walled cavity if the transduction system is linear.
We found that there were no significant distortion products that were generated by the transducer, so we therefore assumed that the system was linear. However, when a similar check was made following data collection, significant DPOAE amplitudes were recorded across the frequency spectrum from 2211 to 17675 Hz, with amplitudes ranging from -13 to 10 dB SPL. This suggests that at some point during data collection the system may have become nonlinear.
Two possible explanations of this are standing waves and electrical interference. Standing waves are cancellations and reinforcements of sound waves due High Frequency Correlations 34 to reflections or interactions between the stimulus and tympanic membrane (Siegel, 1994) . Standing waves can be averaged into amplitude measurements, causing the response to be underestimated or overestimated in interpretation.
Even when a transducer is designed for optimal conditions, a strong input signal can drive a transducer to saturation. When saturation occurs, there will be distortion of the output waveform, so that it will not have the same shape as the input waveform (Gibilisco, 1993) . However, our transducer output was only 65 dB SPL, while the standard output values are acceptable up to 75 dB SPL without driving the transducer into saturation. Therefore, transducer saturation was most likely not a factor.
Due to the fact that there was change in transducer output calibration measures between initiation and completion of the study, this most likely compromised our data accuracy. Since our Intelligent Hearing Systems equipment was producing artifacts, caution should be used that emissions measured are actual measurements and are not artifacts.
High frequency OAE equipment should come equipped with a fool proof method of calibration. It is recommended that future protocols include a daily coupler calibration in addition to an in-the-ear calibration measure before acquiring data on each subj ect.
High frequency DPOAE's and high frequency pure tone audiometry should be used in future studies to evaluate correlational relationships for use in ototoxicity monitoring with different age groups. With properly functioning equipment, this
